SCOPUS 정보 검색 플랫폼

Acta Diabetologica

Volumn 54, Issue 4, 2017, Pages 411-413

Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials

(4) Monami, Matteo a Zannoni, Stefania a Nreu, Besmir a Mannucci, Edoardo a

a Careggi Teaching Hospital (Italy)

Author keywords

Diabetic ketoacidosis; Hypoglycemic agents; Intervention study

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN;

ADVERSE DRUG REACTION; ARTICLE; FOLLOW UP; FOOT AMPUTATION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TOE; TREATMENT DURATION;

EID: 84992146453 PISSN: 09405429 EISSN: 14325233 Source Type: Journal
DOI: 10.1007/s00592-016-0928-z Document Type: Article

Times cited : (13)

References (5)

1
- 84892477577
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- COI: 1:CAS:528:DC%2BC2cXptFWgsQ%3D%3D, PID: 23906415
- Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG PIO™ trial investigators (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16:147–158
- (2014) Diabetes Obes Metab , vol.16 , pp. 147-158
- Kovacs, C.S.¹ Seshiah, V.² Swallow, R.³ Jones, R.⁴ Rattunde, H.⁵ Woerle, H.J.⁶ Broedl, U.C.⁷

2
- 84983201802
- Empagliflozin as add-on to metformin in people with Type 2 diabetes
- COI: 1:CAS:528:DC%2BC2MXhvVyitLvE, PID: 26031566
- Merker L, Häring HU, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC, EMPA-REG EXTEND™ MET investigators (2015) Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet Med 32:1555–1567
- (2015) Diabet Med , vol.32 , pp. 1555-1567
- Merker, L.¹ Häring, H.U.² Christiansen, A.V.³ Roux, F.⁴ Salsali, A.⁵ Kim, G.⁶ Meinicke, T.⁷ Woerle, H.J.⁸ Broedl, U.C.⁹

3
- 84944800184
- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
- COI: 1:CAS:528:DC%2BC28XntVSkurs%3D, PID: 26378978
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
- (2015) N Engl J Med , vol.373 , pp. 2117-2128
- Zinman, B.¹ Wanner, C.² Lachin, J.M.³ Fitchett, D.⁴ Bluhmki, E.⁵ Hantel, S.⁶ Mattheus, M.⁷ Devins, T.⁸ Johansen, O.E.⁹ Woerle, H.J.¹⁰ Broedl, U.C.¹¹ Inzucchi, S.E.¹²

4
- 84928176749
- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin
- COI: 1:CAS:528:DC%2BC2MXksFyktrc%3D
- DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC (2015) Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabet esCare 38:384–393
- (2015) Diabet esCare , vol.38 , pp. 384-393
- DeFronzo, R.A.¹ Lewin, A.² Patel, S.³ Liu, D.⁴ Kaste, R.⁵ Woerle, H.J.⁶ Broedl, U.C.⁷

5
- 84928199102
- Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes
- Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC (2015) Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 3:394–402
- (2015) Diabetes Care , vol.3 , pp. 394-402
- Lewin, A.¹ DeFronzo, R.A.² Patel, S.³ Liu, D.⁴ Kaste, R.⁵ Woerle, H.J.⁶ Broedl, U.C.⁷

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.